What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of sonrotoclax in combination with zanubrutinib for first-line treatment of CLL/SLL.

Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows improved uMRD rates in CLL/SLL patients with del(17p)/TP53, suggesting enhanced treatment efficacy.

This research aims to evaluate the efficacy and safety of sonrotoclax in combination with zanubrutinib for first-line treatment of CLL/SLL.
Phase 1/1b study (NCT04277637) with a median follow-up of 30.9 months.
Showcased a treatment regimen of zanubrutinib followed by sonrotoclax.
Measured safety and uMRD rates using assessments such as flow cytometry and next generation sequencing.
Overall response rate was 100%, with 55% achieving complete response.
Best uMRD4 rate was 99% overall, and 100% for patients with TP53/del(17p) mutations.
No patients experienced progression, with an estimated PFS of 100% at 30 months.

Tam et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark